NMT PHARMA Participates in 2017 ASCO Annual Meeting in Chicago, June 2nd to 6th, 2017
NMT PHARMA has participated in 2017 ASCO Annual Meeting held from 2ndto 6th June 2017 at McCormick Place, Chicago, USA. More than 38,000 oncology professionals from around the world attended this event presenting and discussing the latest research in treatment and patient care. This is a warm-up event for NMT Pharma as its clinical trial Phase 1 program of camptothecin analogue innovative drug CZ48 will be completed in 2018. The clinical data will be presented in ASCO meeting when it is available.
NMT PHARMA Participates in CPhI Worldwide 2016 Barcelona
NMT PHARMA has participated in CPhI Worldwide held from 4th to 6th October 2016 at Fira de Barcelona Gran Via Conference Centre. The event hosted more than 36,000 visiting pharma professionals over the three days, and gathered about 2,500 exhibitors from 150 countries. NMT PHARMA featured its contract R&D services and licensing of CZ48 oncology drug development program. The Company’s booth hosted many visitors with great interest in the applications of nano-technology in drug particle processing and formulation. NMT PHARMA’s Inhaled Insulin has attracted many enquiries from visitors of various regions.
NMT PHARMA Presents the Applications of Nanotechnology in Drug Delivery and Formulation Development in IFAM 2016 Nanjing Forum
NMT PHARMA was invited to present its applications of nanotechnology in pharmaceuticals in the 2016 International Forum on Advanced Materials (IFAM) held from 24th to 26th September 2016 at Nanjing International Youth Cultural Centre. Mr. David Sher, the managing director of NMT PHARMA was the anchor speaker of the Nanomaterials and Technology sub-Forum chaired by Professor Chen Jianfeng, a member of the Chinese Academy of Engineering and Dean of College of Chemical Engineering at Beijing University of Chemical Technology. In the speech, NMT PHARMA presented its commercial works of applying its proprietary nano-technology of HGCP and Duo-C Technologies to improve the drug delivery and formulation development.
Visit us at CPhI Worldwide!
Visit NMT Pharmaceuticals at stand 3B50!
We are pleased to inform you that we will be exhibiting at CPhI Worldwide, ICSE, InnoPack, P-MEC and FDF 2016 from 4 – 6 October 2016 in Fira Gran Via, Barcelona, Spain.
We would like to invite you to our stand 3B50 where we will showcase our latest products, innovations and/or services. Our team will be ready to meet you face-to-face.
We will be waiting for you at stand 3B50.
We look forward to meeting you in October in Barcelona!
2015, August 24
NMT Pharmaceuticals Singapore Announces signing of Letter of Intent with CAO Pharmacueticals USA in Licensing and Development of Anti-cancer Drug CZ-48
Singapore, August 24, 2015 – NMT Pharmaceuticals Pte Ltd (NMT Pharma) announced today that it has signed a legally binding Letter of Intent with US-based CAO Pharmacueticals Inc. (CAO Pharma) for acquiring an exclusive worldwide license right to further develop and market an anti-cancer drug CZ-48 co-developed by CAO Pharma and NMT Pharma.
NMT Pharma and CAO Pharma will enter into agreements that would secure funding needed by CAO Pharma to continue to operate and conduct clinical trials in US. The collaboration is subjected to, among with other requirements, satisfactory completion of due diligence and the execution of a definitive agreement.
CZ-48 is an analogue of camptothecin which is stable and resistant to inactivation while circulating in human bloodstream. This topoisomerase I inhibitor only becomes active when entering in tumor cells. Based on preclinical and previous Phase I clinical trial data, CZ-48 has very low toxicity and mild side effects. CAO Pharma and NMT Pharma have improved the formulation of CZ-48 to increase the bioavailability of the drug so as to further reduce the side effects and improve therapeutic effects. CAO Pharma intends to re-start the Phase I clinical study program with the new CZ-48 formulation within this year.
About NMT Pharmaceuticals Pte Ltd (http://www.nanomt.com)
NMT Pharmaceuticals Pte Ltd is a Singapore and spin off company from the pharmaceutical business division of NanoMaterials Technology Pte Ltd (NMT). As a wholly-owned subsidiary company of NMT, it has a proprietary technology called High Gravity Controlled Precipitation (HGCP) Technology and other patented dispersion technology to improve the bioavailability of micro- and nano-drug particles and formulations.
About CAO Pharmacueticals Inc.
CAO Pharmacueticals Inc. is a start-up company based in Houston, Texas with its business focusing on discovery, development, manufacturing and selling of anti-cancer drugs. The company’s leading drug is CZ-48 which has a broad spectrum of anti-cancer activity against various types of human tumors, such as pancreatic, breast, lung, ovarian, bladder, colon, kidney, liver, stomach, lymph, and head and neck cancers, as well as melanomas. New drug pipelines are being developed and in preparation for IND filling to FDA. The company’s management team is led by Zhisong Cao, PhD., who has more than 20 years of experience in developing anti-cancer drugs. His team has vast experience and knowledge in conducting clinical trials in Phase I and II.
NMT Pharmaceuticals Pte Ltd
Tel: +65 6270-0733
Contact persion: Mr. David Sher
CAO Pharmacueticals Inc.
Tel: +1 (832) 626 2052
Contact person: Dr. Zhisong Cao
2014, January 14
Micro-Sphere Switzerland and NanoMaterials Technology Singapore announces technology partnership to provide particle nanonization-spray drying services
Switzerland, January 14, 2014 – Micro-Sphere SA (MS) and NanoMaterials Technology Private Limited (NMT), jointly announced today that both have formed technology partnership in combining MS’s spray drying technology and NMT’s High Gravity Controlled Precipitation (HGCP) Technology to provide development and manufacturing services to pharmaceutical, skincare and cosmetic companies.
Based on the partnership agreement, both parties shall collaborate together to work on new development or contract manufacturing projects using each party’s proprietary technology. MS shall leverage on its expertise in processing and formulation technologies such as emulsification and spray drying. NMT Singapore shall contribute on its experience in nanonization and formulation, and provide non-exclusive access to MS on its HGCP and related technologies for relevant projects.
“MS as high level contract production and development company is honored to have the possibility to deal with outstanding patented technology owned by NMT and to provide the necessary know-how to enable the positive outcome of the projects”, says Dr. Michele Müller, General Manager of MS.
“We have been working with MS on various projects and are delighted with their spray dying technology, the professionalism and the good quality of works by their team. With this partnership, we can combine the strengths of both companies and offer more solutions to our customers. This will also bring our business and technologies to the next level,” says David Sher, Managing Director of NMT.
About Micro-Sphere SA (http://www.micro-sphere.com)
Micro-Sphere (MS) is located in the south part of Switzerland and has grown up its know-how in spray drying over more than 10 years of practical experience on 90+ different active ingredients in the pharmaceutical field. All operations are performed according to cGMP, meeting the requirements of the Swiss / European and US Authorities (FDA). MS has an important record of activity in the field of high potency actives substances in particular related to the inhalation of dry powders as well to the dispersion of water-insoluble molecules in nano-emulsions.
About NanoMaterials Technology Private Limited (http://www.nanomt.com)
Founded in April 2000, NanoMaterials Technology (NMT) is a Singapore company that specializes in the development and commercialization of nano-materials. NMT has a proprietary technology called High Gravity Controlled Precipitation (HGCP) Technology which is a simple and extremely cost effective mass production technology. The HGCP technology is versatile to be coupled with NMT’s patented dispersion technology and know how to improve the dispersibility of the nano-particles in pharmaceutical and specialty products.
Tel: +41 91 986 7070
Contact person: Dr. S. Console
NanoMaterials Technology Private Limited
Tel: +65 8499 4978
Contact person: Mr. Steve Pang
2013, October 14
NanoMaterials Technology Singapore Signs Clinical Trial Material Supply Agreement for Anti-cancer Drug with CHRISTUS Stehlin Foundation for Cancer Research
SINGAPORE, October 14, 2013 – NanoMaterials Technology Private Limited (NMT), a Singapore-based company, announced today that it has signed an exclusive material supply agreement with Houston-based CHRISTUS Stehlin Foundation for Cancer Research (Stehlin Foundation) on a formulated CZ48 drug for a Phase I clinical (human) trial.
CZ48 is an analog synthesized by the Stehlin Foundation from Camptothecin, an alkaloid extracted from the Chinese tree camptotheca acuminata. When Camptothecin and many of its derivatives are used in humans, the enzymes inactivate some of the drug molecules, eliminating their anti-cancer effect. However, CZ48 is a stable form of Camptothecin, and resistant to inactivation while circulating in the human bloodstream. This topoisomerase I inhibitor has very low toxicity even at more than 20 times the therapeutic dose, and eradicated 29 different human cancers transplanted into the Stehlin Foundation’s athymic nude mice in pre-clinical studies.
The Stehlin Foundation partners with NMT to develop the formulated CZ48 drug using its proprietary High Gravity Controlled Precipitation (HGCP) Technology to elevate absorption by decreasing the size of the CZ48 drug particle. Pre-clinical studies have indicated that a significantly lower dosage with only 25 percent of the original CZ48 molecule is required to achieve complete tumor inhibition using the formulated CZ48 drug.
Under the terms of the agreement, NMT will provide the formulated CZ48 capsules to the Stehlin Foundation for the Phase I study.
“We anticipate launching the Phase I clinical trial with the new formulation of CZ48 during the first quarter of 2014. The study should involve around 30 patients and require 24 months for completion,” says Stehlin Foundation’s President, Robert Anderson. “If Phase I results are as expected, we will move into Phase II.”
“We have been working on the CZ48 drug with the Stehlin Foundation for more than five years. We are glad that our HGCP technology is able to improve bioavailability, reduce drug dosage and side effects, as well as enhance the patient compliance of this highly potential drug. We will continue working closely with the Stehlin Foundation team to support their human clinical trials, commercialization and future developments,” says David Sher, Managing Director of NMT.
Based on IMS Health Reports, anti-cancer drugs will remain the highest grossing sector of the healthcare industry with global sales estimated to reach US$83 billion by 2016. The CZ48 drug, together with Camptothecin and its other derivatives, has a potential market of US$1 billion in USA alone.
About NanoMaterials Technology Private Limited (http://www.nanomt.com)
Founded in April 2000, NanoMaterials Technology (NMT) is a Singapore company that specializes in the development and commercialization of nano-materials. NMT has a proprietary technology called High Gravity Controlled Precipitation (HGCP), which is originally invented and developed by Prof. Jianfeng Chen, one of NMT’s founders, and Beijing University of Chemical Technology, one of its shareholders. The technology was internationalized and further improved by NMT, which results in a mass production technology that is simple and extremely cost effective. The HGCP technology is versatile to be coupled with NMT’s patented dispersion technology and know how to improve the dispersibility of the nano-particles in pharmaceutical and specialty products.
About CHRISTUS Stehlin Foundation for Cancer Research (http://stehlin.org)
Founded in 1969 by surgical oncologist, Dr. John S. Stehlin, Jr., CHRISTUS Stehlin Foundation for Cancer Research (Stehlin Foundation) has been widely recognized in
the scientific world as a pioneer in cancer research and treatment with more than 500 scientific publications. The purpose of the Foundation is to conduct cancer research that can be applied directly to improving the treatment of the patient. All research is clinically oriented. This has shortened the time from the test tube to treatment, resulting in thousands of cancer patients who are alive today. The Stehlin Foundation has a state-of-the-art 27,000 square foot research facility in Houston. Besides drug development, the Foundation also works on various research projects including prostate cancer, hyperthermia, Desmoplastic small-round-cell tumor (DSRCT) and the development of the humanized mouse.
NanoMaterials Technology Private Limited
Tel: +65 9384 1818
Contact person: Ms Grace Yeo
2010, April 8
NanoMaterials Technology Signs Exclusive Licensing Agreement for Hyperlipidemia-controlling Drug with Beijing Winsunny Pharmaceutical
Singapore, April 8, 2010 – NanoMaterials Technology Private Limited (“NMT”)
announced today that it has signed an exclusive licensing agreement with Beijing
Winsunny Pharmaceutical Company Limited (“Winsunny Pharma”) for the use of
its proprietary High Gravity Controlled Precipitation (“HGCP”) Technology to
manufacture, market and distribute a generic version of a world-wide blockbuster
hyperlipidemia-controlling drug in China with a potential market size of over
US$900 million. Currently, there are 90 million patients in China undergoing long
term treatment for hyperlipidemia. The annual growth rate of the patients is about
15 million and it is estimated that the number of patients required the treatment
will reach 200 million in the next 10 years.
Under the terms of the agreement, Winsunny Pharma will pay an undisclosed
upfront fee as well as milestones and royalty payments based on future sales of
the drug. NMT will provide a new formulation that will increase efficacy, lower
drug dosage and provide better patient compliance. Winsunny Pharma will
assume all the costs of development, regulatory and commercialization of the
solid oral dosage formed drug including clinical trials.
“Today’s announcement is an important milestone for NMT in deploying our
HGCP technology in one of the fastest growing and most important markets in
the world for the pharmaceutical sector,” said Dr. Jimmy Yun, CEO of NMT.
“Previously, we had demonstrated the use of HGCP Technology in mass
production of specialty chemicals. This is our first collaboration with Winsunny
Pharma and it provides an opportunity to extend the product range of their
hyperlipidemia-controlling drugs. We believe that this is the beginning of a series
of drugs using our technology to be made available in the market. We look
forward to have more collaboration with Winsunny Pharma in future.”
“We have various late stage developments which have the potential to reach
commercialization in the near future. Currently, we are in talks with
pharmaceutical companies in the US, Europe and China to commercialise
several compounds using HGCP technology,” continued Dr. Yun.
The HGCP Technology allows production of active pharmaceutical ingredient
(“API”) at both low micron and nano-sized range. NMT has demonstrated the
suitability of the technology for processing APIs of both small and macro
molecules to be formulated for solid oral dosage and inhalation forms. The
HGCP Technology is also being used for designing drug particles with good
aerodynamic properties and specific particle size distribution for pulmonary
inhalation. It consolidates the current conventional “crystallization, micronization
and conditioning” manufacturing processes into one-step, which is cost and time
About NanoMaterials Technology Pte Ltd (http://www.nanomt.com)
Founded in April 2000, NanoMaterials Technology (NMT) is a Singapore company that specialises in the development and commercialisation of the production technologies of nano-materials. NMT has a proprietary technology called the High Gravity Controlled Precipitation (HGCP). The result of this breakthrough is a nano-material production technology that is simple, easy to scale up and extremely cost effective. The HGCP Technology is versatile to be coupled with NMT’s dispersion technology and know how to improve the dispersibility of the nano-particles.
About Beijing Winsunny Pharmaceutical Co., Ltd. (http://www.bjwsyy.com)
Founded in February 1999, Winsunny Pharma is a pharmaceutical company in Beijing
and is a subsidiary of Zhejiang NHU Group (http://www.cnhu.com/en). Zhejiang NHU Group is a public-listed company in Shenzhen Stock Exchange, China. Winsunny
Pharma specializes in hyperlipidemia-controlling, high blood pressure, nephrology, CNS and diabetes drugs.
NanoMaterials Technology Pte Ltd
Tel: +65 9384 1818
Contact person: Ms Grace Yeo
2007, October 25
NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company.
NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
Singapore, 25 Oct 2007 – NanoMaterials Technology (“NMT”) announced that it will conduct a feasibility study with a US based emerging pharmaceutical company.
As part of the feasibility agreement, NMT will apply its proprietary technology, High Gravity Controlled Precipitation (HGCP), to the design of drug particles for pulmonary inhalation.
“Altering the particle design of drug compounds changes the physical properties of the drugs and this leads to enhanced drug efficacy and patient compliance,” says Dr Jimmy Yun, the CEO of NMT. NMT’s niche in the pharmaceutical industry is in particle design and the company is currently focusing its development on solid oral and inhalation delivery.
NMT is also currently in talks with pharmaceutical companies in the US and Europe for several development agreements. As part of its drive into the pharmaceutical sector, NMT has appointed John Mitchell and Prof. Dr. Siegfried Neumann to its Scientific Advisory Board (“SAB”).
John Mitchell retired from Pfizer Inc as Senior Vice President and President/Team Leader, Pfizer Global Manufacturing at the end of 2004. While at Pfizer, he was responsible for worldwide manufacturing operations that produced pharmaceutical, consumer healthcare and animal health products, encompassing plants and logistics centers at more than 120 sites in 40 countries.
John holds a Bachelor of Engineering degree from Yale University and an honorary Doctor of Laws degree from the National University of Ireland.
Prof. Neumann is currently a Senior Consultant of R&D at Merck KGaA. At Merck KGaA, Prof. Neumann was a group leader in R&D in the Diagnostic Division until 1985. He subsequently headed up the Immunochemistry Department in Preclinical Research at Merck Pharma until 1989 when he returned as the Head of R&D of the Diagnostic Division. In 1994, he moved on to head up the Business Development and Research Alliance Office in Specialty Chemistry and Biotechnology. Prof. Neumann has an established track record in technology scouting and evaluation, and participates in various national and international expert panels in the field of biotechnology.
Prof. Neumann received his PhD in biochemistry from the University of Bochum, Germany in 1971.
“It is a great pleasure and honour for us to have both John and Prof. Neumann joining our SAB. Their addition to our SAB is invaluable as they bring with them broad and in-depth experience in the pharmaceutical industry,” says Dr. Yun.
About NanoMaterials Technology Pte Ltd (www.nanomt.com)
Founded in April 2000, NanoMaterials Technology (NMT) is a Singapore company that specialises in the development and commercialisation of the production technologies of nanomaterials. NMT has a proprietary technology called the High Gravity Controlled Precipitation (HGCP). The result of this breakthrough is a nanomaterial production technology that is simple, easy to scale up and extremely cost effective.
2006, May 8
NanoMaterials Technology and Sydney University Awarded Australian Research Council Linkage Grant.
Singapore, 8 May 2006 – Singapore-based NanoMaterials Technology Pte Ltd (“NMT”), together with the University of Sydney, has been awarded an Australian Research Council Linkage Grant, with a total project funding of US$333,000. This is for research into the high gravity precipitation of nanoparticles for pulmonary drug delivery.
This collaborative project, headed by Associate Professor Hak-Kim Chan from the Faculty Pharmacy of the University of Sydney and Dr Jimmy Yun from NMT, aims to explore the huge market potential of drug delivery by inhalation aerosols using nanoparticles. Nanoparticles can penetrate deeper into the lung where they deposit and dissolve faster for enhanced therapeutic effects. The project will focus on both the production process and the particle properties for aerosol administration.
Contact Details: NanoMaterials Technology Pte Ltd
Tel: (65) 9384 1818
Contact person: Ms Grace Yeo
Cogent Communications Pte Ltd
Tel: (65) 6323 3060
Contact person: Ms Celine Ooi
About NanoMaterials Technology Pte Ltd (“NMT”) www.nanomt.com
Founded in April 2000, NanoMaterials Technology (NMT) is a Singapore company that specialises in the development and commercialisation of the production technologies of nanomaterials.
NMT has a proprietary technology called the High Gravity Controlled Precipitation (HGCP). The result of this breakthrough is a nanomaterial production technology that is simple, easy to scale up and extremely cost effective. NMT places great significance in the research and development in nanotechnology.
- Company Profile
- R&D Services